Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer

Author： Reckamp Karen L.   Koczywas Marianna   Cristea Mihaela C.   Dowell Jonathan E.   Wang He-Jing   Gardner Brian K.   Milne Ginger L.   Figlin Robert A.   Fishbein Michael C.   Elashoff Robert M.   Dubinett Steven M.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|18|3298-3306

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.18, 2015-09, pp. : 3298-3306

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)

By Tran Hai   Zinner Ralph   Blumenschein George   Oh Yun   Papadimitrakopoulou Vassiliki   Kim Edward   Lu Charles   Malik Mubashira   Lum Bert   Herbst Roy  

Investigational New Drugs, Vol. 29, Iss. 3, 2011-06 ,pp. : 499-505

Springer Publishing Company

Access to resources Recommend Favorite

Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer

By Vansteenkiste Johan   Canon Jean-Luc   Riska Henrik   Pirker Robert   Peterson Patrick   John William   Mali Pekka   Lahn Michael  

Investigational New Drugs, Vol. 23, Iss. 3, 2005-06 ,pp. : 263-269

Springer Publishing Company

Access to resources Recommend Favorite

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

By Reckamp Karen L.   Giaccone Giuseppe   Camidge D. Ross   Gadgeel Shirish M.   Khuri Fadlo R.   Engelman Jeff A.   Koczywas Marianna   Rajan Arun   Campbell Alicyn K.   Gernhardt Diana   Ruiz-Garcia Ana   Letrent Stephen   Liang Jane   Taylor Ian   O'Connell Joseph P.   Jänne Pasi A.  

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1145-1154

Blackwell Publishing

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer

By Argiris Athanassios   Kut Victoria   Luong Lynn   Avram Michael  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 203-212

Springer Publishing Company

Access to resources Recommend Favorite

A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer

By Moulder Stacy   Dhillon Navneet   Ng Chaan   Hong David   Wheler Jennifer   Naing Aung   Tse Susan   La Paglia Amy   Dorr Robert   Hersh Evan   Boytim Michelle   Kurzrock Razelle  

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 634-640

Springer Publishing Company

Access to resources Recommend Favorite